Patients with relapsed or refractory mantle cell lymphoma may receive benefit from bortezomib

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1544, 2006-01, pp. : 13-13

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Temsirolimus: In Relapsed and/or Refractory Mantle Cell Lymphoma

By Hoy Sheridan M. McKeage Kate

Drugs, Vol. 70, Iss. 14, 2010-10 ,pp. : 1819-1829

Adis International

Access to resources Recommend Favorite

A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network study

Cancer, Vol. 121, Iss. 19, 2015-10 ,pp. : 3465-3471

Blackwell Publishing

Access to resources Recommend Favorite

B-cell lymphoma vaccination may benefit certain patients with NHL

Inpharma, Vol. 1, Iss. 1475, 2005-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Preliminary Experience with Yttrium-90-labelled Rituximab (Chimeric Anti CD-20 Antibody) in Patients with Relapsed and Refractory B Cell Non-Hodgkins Lymphoma

Current Radiopharmaceuticals, Vol. 9, Iss. 2, 2016-08 ,pp. : 160-168

Bentham Science Publishers

Access to resources Recommend Favorite

Feasibility of myeloablative allogeneic hematopoietic cell transplantation from unrelated donors for patients with relapsed or refractory multiple myeloma

Hematological Oncology (Electronic), Vol. 36, Iss. 1, 2018-02 ,pp. : 363-365

John Wiley & Sons Inc

Access to resources Recommend Favorite